Scholars@Duke

Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

Publication ,  Journal Article
Anderson, JR; Barr, FG; Hawkins, DS; Parham, DM; Skapek, SX; Triche, TJ
Published in: J Clin Oncol
October 10, 2010
Published version (DOI) Link to item

Duke Scholars

Stephen Xavier Skapek
Author Stephen Xavier Skapek Pediatrics, Transplant and Cellular Therapy

Published In

J Clin Oncol

DOI

10.1200/JCO.2010.30.5466

EISSN

1527-7755

Publication Date

October 10, 2010

Volume

28

Issue

29

Start / End Page

e587 / e588

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Risk Assessment
  • Rhabdomyosarcoma, Embryonal
  • Rhabdomyosarcoma, Alveolar
  • Paired Box Transcription Factors
  • Oncology & Carcinogenesis
  • Oncogene Proteins, Fusion
  • Humans
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Anderson, J. R., Barr, F. G., Hawkins, D. S., Parham, D. M., Skapek, S. X., & Triche, T. J. (2010). Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol, 28(29), e587–e588. https://doi.org/10.1200/JCO.2010.30.5466
Anderson, James R., Frederic G. Barr, Douglas S. Hawkins, David M. Parham, Stephen X. Skapek, and Timothy J. Triche. “Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.” J Clin Oncol 28, no. 29 (October 10, 2010): e587–88. https://doi.org/10.1200/JCO.2010.30.5466.
Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol. 2010 Oct 10;28(29):e587–8.
Anderson, James R., et al. “Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.” J Clin Oncol, vol. 28, no. 29, Oct. 2010, pp. e587–88. Pubmed, doi:10.1200/JCO.2010.30.5466.
Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol. 2010 Oct 10;28(29):e587–e588.

Published In

J Clin Oncol

DOI

10.1200/JCO.2010.30.5466

EISSN

1527-7755

Publication Date

October 10, 2010

Volume

28

Issue

29

Start / End Page

e587 / e588

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Risk Assessment
  • Rhabdomyosarcoma, Embryonal
  • Rhabdomyosarcoma, Alveolar
  • Paired Box Transcription Factors
  • Oncology & Carcinogenesis
  • Oncogene Proteins, Fusion
  • Humans
  • Disease-Free Survival